Literature DB >> 20236729

Can 'search and destroy' reduce nosocomial methicillin-resistant Staphylococcus aureus in an Irish hospital?

A Higgins1, M Lynch, G Gethin.   

Abstract

In Ireland, the Department of Health and Children recommends admission screening of patients at increased risk of methicillin-resistant Staphylococcus aureus (MRSA), isolation of these patients until proven negative, and eradication of any MRSA identified. These actions form the basis of a programme called 'search and destroy' that has successfully reduced MRSA in Scandinavia. There is, however, very little information published on the use of search and destroy in Ireland. This study was carried out using a quantitative, quasi-experimental design in the form of an interventional cohort study. The effect of reducing the turnaround time for MRSA results (2007) and the introduction of pre-emptive isolation (2008) was examined in a hospital with an established admission screening programme for MRSA. Rates of MRSA infection and colonisation were monitored post-intervention and compared to baseline rates prior to the intervention (2005-2006). Rates of hospital-acquired (nosocomial) MRSA infections and colonisation fell in both 2007 and 2008. However, due to the quasi-experimental design of the study and the low endemic level of MRSA in the hospital, a causal link could not be established. (c) 2009 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20236729     DOI: 10.1016/j.jhin.2009.12.014

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  2 in total

1.  Hospital networks and the dispersal of hospital-acquired pathogens by patient transfer.

Authors:  Tjibbe Donker; Jacco Wallinga; Richard Slack; Hajo Grundmann
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

2.  The gut is the epicentre of antibiotic resistance.

Authors:  Jean Carlet
Journal:  Antimicrob Resist Infect Control       Date:  2012-11-27       Impact factor: 4.887

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.